Ki20227 是一种高效的、口服具有活性的、选择性的CSF1R(c-Fms 酪氨酸激酶)抑制剂，对 CSF1R，VEGFR2，c-Kit和PDGFRβ的IC50分别为 2 nM，12 nM，451 nM 和 217 nM。它可以阻止破骨细胞分化和溶骨性破坏。

Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively.

Ki20227 hasn't inhibition for other kinases tested, such as EGFR, Fms-like tyrosine kinase-3, or c-Src (c-src proto-oncogene product). Ki20227 also inhibits the M-CSF-dependent growth of M-NFS-60 cells but not the M-CSF-independent growth of A375 human melanoma cells in vitro. Ki20227 has an inhibition against M-CSF-dependent reactions, such as lipopolysaccharide-induced TNF-α production, which was enhanced by M-CSF in vitro.

Ki20227 reduces the number of tartrate-resistant acid phosphatase-positive osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats. Furthermore, in the Ki20227-treated mice, the number of CD11b(+), Gr-1(+), and Ly-6 g(+) cells in the spleen were decreased and the CII-induced cytokine production in splenocytes isolated from the Ki20227-treated arthritic mice was also reduced. In EAE animal model, Ki20227 inhibits the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses.

623142-96-1

C24H24N4O5S

480.54

N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲

DMSO:7.2 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years